Showing 4121-4130 of 5771 results for "".
- CooperVision Expands Leadership Teamhttps://modernod.com/news/coopervision-expands-leadership-team/2479259/CooperVision announced the hiring of Kamela Bearlin as Senior Global Brand Director, 1 Day Brands; and Jennifer Lambert as Senior Global Brand Director, Myopia Management; and promoted Elizabeth Lumb, BSc(Hons) MCOptom, FBCLA, to Director of Global Professional Affairs, Myopia Management.
- AcuFocus Appoints Industry Leader John Garland as Global Vice President of Saleshttps://modernod.com/news/acufocus-appoints-industry-leader-john-garland-as-global-vice-president-of-sales/2479257/AcuFocus announced that it has appointed John Garland as its Global Vice President of Sales. In his new role, he will be responsible for global sales strategy and will focus initially on building the US sales field team. Mr. Garland brings more than 30 years of experience to the position w
- Avellino Launches AvaGen as First Genetic Test to Quantify Keratoconus Risk and Presence of Corneal Dystrophieshttps://modernod.com/news/avellino-launches-avagen-as-first-genetic-test-to-quantify-keratoconus-risk-and-presence-of-corneal-dystrophies/2479255/Avellino Lab USA announced full nationwide availability in the US of AvaGen, as the first genetic test that helps determine a patient’s risk of keratoconus and the presence of other corneal dystrophies. The test allows for more confident management and treatment for patients with these conditions
- Johnson & Johnson Vision Expands “Sight For Kids” Program and Unveils “Vision for Good” Community Impact Reporthttps://modernod.com/news/johnson-johnson-vision-expands-sight-for-kids-program-and-unveils-vision-for-good-community-impact-report/2479256/Johnson & Johnson Vision announced the expansion of nonprofit program
- Notal Vision Raises Up to $60 Million to Support Development of its Home OCT Technologyhttps://modernod.com/news/notal-vision-raises-up-to-60-million-to-support-development-of-its-home-oct-technology/2479251/Notal Vision announced the closing of a Series D financing to support the commercial growth of the company’s current service, the ForeseeHome AMD Monitoring Program, as well as the go-to-market strategy for its Home OCT pipeline technology. The financing was co-led by Soleus Capital and the compa
- Myra Vision Closes $17M In Series A Financing to Advance Glaucoma Devicehttps://modernod.com/news/myra-vision-closes-17m-in-series-a-financing-to-advance-glaucoma-device/2479247/Myra Vision announced the closing of its $17 million Series A financing, which will be used to advance product development, scale infrastructure, and expand their team in order to support the development of the first of its kind glaucoma treatment device. The financi
- Neurophth Therapeutics and Hopstem Biotechnology Partner to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for Ocular Diseaseshttps://modernod.com/news/neurophth-therapeutics-and-hopstem-biotechnology-partner-to-develop-human-induced-pluripotent-stem-cell-derived-therapies-for-ocular-diseases/2479248/Neurophth Biotechnology and Hopstem Biotechnology announced a strategic partnership aiming to provide human iPSC-derived cell therapy for ocular diseases. The partnership leverages Neurophth’s experience in global gene/cell therapy drugs development and understanding of ophthalmic di
- Nicox’s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicoxs-completes-pre-defined-enrollment-of-ncx-4251-mississippi-phase-2b-blepharitis-trial/2479250/Nicox announced that more than 200 patients, the pre-defined target, have been randomized in the NCX 4251 Mississippi phase 2b blepharitis clinical trial. Topline results are expected to be announced during September 2021. “Blepharitis is a highly prevalent eye condition with frequent exac
- GSK, Sanofi Start Phase 3 Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/gsk-sanofi-start-phase-3-study-of-covid-19-vaccine-candidate/2479245/GlaxoSmithKline and Sanofi announced Thursday the start of enrollment in a phase 3 study investigating their adjuvanted recombinant-protein COVID-19 vaccine candidate, according to a FirstWord report. The trial will include more than 35,000 volunteers aged 18 and older from several countries, inc
- Samsara Vision: Patients Blinded by Macular Degeneration May Benefit From Implant Technologyhttps://modernod.com/news/samsara-vision-reports-that-patients-blinded-by-macular-degeneration-benefit-from-milestone-in-implant-technology/2479242/Samsara Vision announced the first successful clinical cases in Europe using their smaller-incision new-generation implantable miniature telescope (SING IMT) for people living with late-stage age-related macular degeneration (AMD). The SING IMT, performed with the TSert delivery system, was succe